United Therapeutics Corporation


SKU: UTHR Category:


United Therapeutics Corporation: Initiation Of Coverage – 6 Biggest Factors Driving Its Future Growth!


This is our first report on biotech major, United Therapeutics Corporation (UTC). The company posted solid financial results for the fourth quarter of 2023, marking the third consecutive quarter of record revenue, and the second consecutive year of record income. The company achieved over 20% growth in both quarterly and annual revenue for the fourth quarter and the full year. One of the significant contributors to this growth was the company’s Tyvaso DPI business, valued at $15 billion externally through a royalty transaction executed by their partners at MannKind Corporation. This valuation, which exceeds UTC’s current market cap, provides important external validation of the value of Tyvaso DPI.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!